tiprankstipranks
NeuroOne Medical Technologies (NMTC)
NASDAQ:NMTC
US Market
NMTC
NeuroOne Medical Technologies
RESEARCH TOOLSreports
Want to see NMTC full AI Analyst Report?

NeuroOne Medical Technologies (NMTC) Stock Forecast & Price Target

195 Followers
See the Price Targets and Ratings of:

NMTC Analyst Ratings

Strong Buy
3Ratings
Strong Buy
3 Buy
0 Hold
0 Sell
Based on 3 analysts giving stock ratings to
NeuroOne
Medical Technologies
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

NMTC Stock 12 Month Forecast

Average Price Target

$9.67
▲(99.72% Upside)
Based on 3 Wall Street analysts offering 12 month price targets for NeuroOne Medical Technologies in the last 3 months. The average price target is $9.67 with a high forecast of $13.00 and a low forecast of $8.00. The average price target represents a 99.72% change from the last price of $4.84.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","8":"$8","11":"$11","14":"$14"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$13.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.666666666666666,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,5,8,11,14],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.35,5.015384615384615,5.680769230769231,6.346153846153846,7.0115384615384615,7.676923076923077,8.342307692307692,9.007692307692308,9.673076923076923,10.338461538461539,11.003846153846155,11.669230769230769,12.334615384615386,{"y":13,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.35,4.758974358974359,5.167948717948717,5.576923076923077,5.985897435897435,6.394871794871794,6.803846153846154,7.212820512820512,7.621794871794871,8.03076923076923,8.439743589743589,8.848717948717947,9.257692307692308,{"y":9.666666666666666,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.35,4.63076923076923,4.911538461538461,5.192307692307692,5.473076923076922,5.753846153846153,6.0346153846153845,6.315384615384615,6.596153846153846,6.8769230769230765,7.157692307692307,7.438461538461539,7.719230769230769,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.707,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.557,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.2,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.548,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.585,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.335,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.752,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.086,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.548,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.009,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.002,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.812,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.35,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$13.00Average Price Target$9.67Lowest Price Target$8.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
JonesTrading Analyst forecast on NMTC
Justin Walsh
JonesTrading
JonesTrading
$8
Buy
65.29%
Upside
Reiterated
05/13/26
Analysts Offer Insights on Healthcare Companies: Organigram Global (NASDAQ: OGI) and NeuroOne Medical Technologies (NASDAQ: NMTC)
Ladenburg Thalmann & Co. Analyst forecast on NMTC
Jeffrey Cohen
Ladenburg Thalmann & Co.
Ladenburg Thalmann & Co.
$1.6→$8
Buy
65.29%
Upside
Reiterated
05/13/26
NeuroOne Medical target adjusted to $8 from $1.60 at LadenburgNeuroOne Medical target adjusted to $8 from $1.60 at Ladenburg
Maxim Group Analyst forecast on NMTC
Anthony Vendetti
Maxim Group
Maxim Group
$13
Buy
168.60%
Upside
Reiterated
05/13/26
Analysts Offer Insights on Healthcare Companies: DarioHealth (NASDAQ: DRIO), NeuroOne Medical Technologies (NASDAQ: NMTC) and COMPASS Pathways (NASDAQ: CMPS)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
JonesTrading Analyst forecast on NMTC
Justin Walsh
JonesTrading
JonesTrading
$8
Buy
65.29%
Upside
Reiterated
05/13/26
Analysts Offer Insights on Healthcare Companies: Organigram Global (NASDAQ: OGI) and NeuroOne Medical Technologies (NASDAQ: NMTC)
Ladenburg Thalmann & Co. Analyst forecast on NMTC
Jeffrey Cohen
Ladenburg Thalmann & Co.
Ladenburg Thalmann & Co.
$1.6→$8
Buy
65.29%
Upside
Reiterated
05/13/26
NeuroOne Medical target adjusted to $8 from $1.60 at LadenburgNeuroOne Medical target adjusted to $8 from $1.60 at Ladenburg
Maxim Group Analyst forecast on NMTC
Anthony Vendetti
Maxim Group
Maxim Group
$13
Buy
168.60%
Upside
Reiterated
05/13/26
Analysts Offer Insights on Healthcare Companies: DarioHealth (NASDAQ: DRIO), NeuroOne Medical Technologies (NASDAQ: NMTC) and COMPASS Pathways (NASDAQ: CMPS)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering NeuroOne Medical Technologies

3 Months
Anthony VendettiMaxim Group
Success Rate
2/5 ratings generated profit
40%
Average Return
-7.82%
Copying Anthony Vendetti's trades and holding each position for 3 Months would result in 40.00% of your transactions generating a profit, with an average return of -7.82% per trade.
1 Year
Justin WalshJonesTrading
Success Rate
1/3 ratings generated profit
33%
Average Return
-7.00%
Copying Justin Walsh's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -7.00% per trade.
2 Years
Justin WalshJonesTrading
Success Rate
1/3 ratings generated profit
33%
Average Return
-7.00%
Copying Justin Walsh's trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of -7.00% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NMTC Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
1
2
2
3
5
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
1
2
2
3
5
In the current month, NMTC has received 5 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. NMTC average Analyst price target in the past 3 months is 9.67.
Each month's total comprises the sum of three months' worth of ratings.

NMTC Financial Forecast

NMTC Earnings Forecast

Next quarter’s earnings estimate for NMTC is -$0.58 with a range of -$1.32 to -$0.17. The previous quarter’s EPS was -$0.25. NMTC beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year NMTC has Performed in-line its overall industry.
Next quarter’s earnings estimate for NMTC is -$0.58 with a range of -$1.32 to -$0.17. The previous quarter’s EPS was -$0.25. NMTC beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year NMTC has Performed in-line its overall industry.

NMTC Sales Forecast

Next quarter’s sales forecast for NMTC is $2.55M with a range of $2.51M to $2.58M. The previous quarter’s sales results were $2.39M. NMTC beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year NMTC has Performed in-line its overall industry.
Next quarter’s sales forecast for NMTC is $2.55M with a range of $2.51M to $2.58M. The previous quarter’s sales results were $2.39M. NMTC beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year NMTC has Performed in-line its overall industry.

NMTC Stock Forecast FAQ

What is NMTC’s average 12-month price target, according to analysts?
Based on analyst ratings, NeuroOne Medical Technologies’s 12-month average price target is 9.67.
    What is NMTC’s upside potential, based on the analysts’ average price target?
    NeuroOne Medical Technologies has 99.72% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is NMTC a Buy, Sell or Hold?
          NeuroOne Medical Technologies has a consensus rating of Strong Buy which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.
            What is NeuroOne Medical Technologies’s price target?
            The average price target for NeuroOne Medical Technologies is 9.67. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $13.00 ,the lowest forecast is $8.00. The average price target represents 99.72% Increase from the current price of $4.84.
              What do analysts say about NeuroOne Medical Technologies?
              NeuroOne Medical Technologies’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
                How can I buy shares of NMTC?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.